Trials / Completed
CompletedNCT00103545
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response
A Phase I/II Trial of ACA 125 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 36 (planned)
- Sponsor
- AGO Study Group · Academic / Other
- Sex
- Female
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to use an immunologic approach following the treatment for recurrent disease in patients with ovarian, fallopian tube, or peritoneal cancer.
Detailed description
Patients with epithelial ovarian, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70% will eventually relapse. Many patients respond to additional cytotoxic treatment with partial or complete responses, yet approximately 100% of these patients will ultimately progress. Novel consolidation strategies following treatment for recurrent disease are needed and an immunologic approach is an attractive option.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ACA 125 |
Timeline
- Start date
- 2003-07-01
- Completion
- 2004-08-01
- First posted
- 2005-02-11
- Last updated
- 2006-10-02
Locations
11 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00103545. Inclusion in this directory is not an endorsement.